Catalent Pharma Solutions
About Catalent Pharma Solutions
256 articles with Catalent Pharma Solutions
-
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.
-
Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2/19/2021
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the SVB Leerink 10th Annual Global Healthcare Conference at 11:20 a.m. ET on February 25, 2021.
-
SK Capital Announces Agreement to Acquire Catalent’s Blow-Fill-Seal Sterile CDMO Business
1/6/2021
SK Capital Partners LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that funds it advises have signed a definitive agreement to acquire the Blow-Fill-Seal Sterile Contract Development and Manufacturing Business from Catalent Pharma Solutions, LLC.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
-
The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.
-
With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
-
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-rated Generic Version of ProAir® HFA
2/25/2020
Perrigo Company plc and its partner, Catalent Pharma Solutions, today announced that the U.S. Food and Drug Administration has approved Perrigo's abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA*.
-
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2028
2/20/2020
Feb. 20, 2020 18:04 UTC SOMERSET, N.J.--( BUSINESS WIRE )-- Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of €825.0 million in aggregate principa
-
Catalent Announces Launch of Private Offering of €450 Million of Senior Unsecured Notes Due 2028
2/19/2020
Catalent, Inc. announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., intends to offer, subject to market and other conditions, €450.0 million in aggregate principal amount of senior unsecured notes due 2028 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended.
-
Orgenesis completes sale of Masthercell subsidiary; receives approximately USD 127 million in net proceeds
2/11/2020
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership
-
Catalent Further Strengthens Biologics Business with Key Senior Appointments
1/16/2020
Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring.
-
Catalent, Inc. Announces Second Quarter Fiscal Year 2020 Earnings Conference Webcast
1/15/2020
The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.
-
Catalent, Inc. Reports First Quarter Fiscal 2020 Results
11/5/2019
Q1'20 revenue of $664.7 million increased 20% as-reported, or 22% in constant currency, from Q1'19.
-
Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027
6/24/2019
Catalent, Inc. announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of senior unsecured notes due 2027 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended.
-
The facility has acted as one of Bristol-Myers Squibb’s primary launch facilities for new drugs. After the deal is closed, Catalent will continue to manufacture Bristol-Myers Squibb’s current product portfolio at that location.
-
Catalent, Inc. to Present at the Jefferies Healthcare Conference
5/30/2019
Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Jefferies Healthcare Conference at 3:00 p.m. ET on Thursday, June 6, 2019 in New York, NY.
-
Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion
5/20/2019
Paragon Bioservices is a leading viral vector development and manufacturing partner for gene therapies.